AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31706786
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose lurasidone (80mg)
Trial: 31706786
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose lurasidone (240mg)
Trial: 17268411
Drug: Lutein 18
RxNorm normalized name: lutein 18.6 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein 18 mg
Trial: 17268411
Drug: Lutein 36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein 36 mg
Trial: 11376504
Drug: PDA (Automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA (Automated Protamine Dose Assay)
Trial: 11376504
Drug: Empirical protamine
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical protamine ratio (1 mg protamine/100 U heparin)
Trial: 11376504
Drug: PDA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA and ACT after protamine administration
Trial: 7945787
Drug: Oral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenge with aspirin
Trial: 7945787
Drug: Oral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenge with sulfites
Trial: 7945787
Drug: Oral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenge with NSAIDs or food and drug additives
Trial: 28843136
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for BED
Trial: 21057697
Drug: Desmopressin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.4 microg/kg after administration of protamine (group C)
Trial: 21057697
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy (group A)
Trial: 21057697
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg qd (group B)
Trial: 21057697
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg qd (group C)
Trial: 17922971
Drug: FEV(1) >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEV(1) > 2 L
Trial: 15727952
Drug: Troglitazone (PPARgamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (PPARgamma agonist), 5 microM palmitate, chronic treatment for 4 days
Trial: 15727952
Drug: Troglitazone (PPARgamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (PPARgamma agonist)
Trial: 31900172
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of primaquine (0.5 mg/kg/day)
Trial: 23488362
Drug: Post-discharge telephone
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discharge telephone intervention delivered weekly for the first month and then monthly until the third month (experimental group)
Trial: 18617627
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise training and weight loss (WLEX; n = 17)
Trial: 18617627
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (EX; n = 36) and Combination (WLEX; n = 17)
Trial: 16210715
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid supplementation initiated during the first trimester with 30 mg Fe plus 175 microg folic acid
Trial: 16210715
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid supplementation initiated during the first trimester with 60 mg Fe plus 350 microg folic acid
Trial: 16210715
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid supplementation initiated at week 20 with 30 mg Fe plus 175 microg folic acid
Trial: 16210715
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid supplementation initiated at week 20 with 60 mg Fe plus 350 microg folic acid
Trial: 12821469
Drug: Gentamicin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (3 mg/kg/day intravenously for 14 days) and Doxycycline (200 mg/day orally for 28 days)
Trial: 11143912
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy for PLB
Trial: 11143912
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy for ESNHL
Trial: 11143912
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy for SLB
Trial: 8841903
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of 2 or more modes
Trial: 8841903
Drug: various modes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: various modes of oral hygiene education
Trial: 1617028
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg methylprednisolone in 10 ml NaCl 0.9% (corticoid group)
Trial: 1617028
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml NaCl (NaCl group)
Trial: 6541715
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml of essential amino acids
Trial: 6541715
Drug: Normal postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal postoperative electrolyte solutions alone
Trial: 30212981
Drug: AML/VAL 5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AML/VAL 5/160 mg FDC
Trial: 30212981
Drug: VAL/HCTZ 160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAL/HCTZ 160/12.5 mg FDC
Trial: 26704145
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received a drop of sterile nonpreserved 0.9% sodium chloride solution
Trial: 24251556
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT group)
Trial: 22088556
Drug: AZD3480 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 (5 mg, 20 mg, and 35/100 mg depending on CYP2D6 metabolic status)
Trial: 21053620
Drug: Haloperidol and
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol and trihexyphenidyl (Western medicine group)
Trial: 12165970
Drug: 4-week stress
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week stress management treatment
Trial: 1759830
Drug: Ceftibuten (CFB)
RxNorm normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftibuten (CFB) single oral dose of 4.5 or 9.0 mg/kg
Trial: 6818599
Drug: Test dose
RxNorm normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test dose of ethanol
Trial: 30669469
Drug: 140 g
RxNorm normalized name: STEARIC ACID 1 g in 140 g TOPICAL LIQUID [Body Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 g of whole blueberries
Trial: 30669469
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (matched for calories, sugars, and fiber)
Trial: 17878209
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with methotrexate and ciclosporine
Trial: 17878209
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with methotrexate and placebo-ciclosporine
Trial: 12605235
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil 0.05 mg
Trial: 12605235
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil 0.1 mg
Trial: 12605235
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil 0.2 mg
Trial: 12605235
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil 0.3 mg
Trial: 10838535
Drug: Cardioplegic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioplegic group with 42 mmol/L glucose and 10 IU/L insulin
Trial: 10838535
Drug: Cardioplegic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioplegic group with 84 mmol/L glucose and 10 IU/L insulin
Trial: 10838535
Drug: Cardioplegic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioplegic group with 42 mmol/L glucose without insulin
Trial: 10838535
Drug: Cardioplegic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioplegic group with 84 mmol/L glucose without insulin
Trial: 8482629
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy doses of < or = 54 Gy
Trial: 8482629
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy doses > or = 57.6 Gy
Trial: 8482629
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy doses > or = 63 Gy
Trial: 8482629
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy doses 57.6 Gy with a boost of 63 Gy
Trial: 8482629
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation above 63 Gy at 1.8 Gy per day
Trial: 28975842
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care including weekly group exercise
Trial: 15580967
Drug: Opegan (Santen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opegan (Santen Pharmaceuticals, Osaka, Japan)
Trial: 9228196
Drug: Atropine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Trial: 9228196
Drug: Atropine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Trial: 9228196
Drug: Noradrenaline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Trial: 9228196
Drug: Tyramine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Trial: 7962379
Drug: Buserelin, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin, 500 micrograms subcutaneously daily, with variable amounts of menopausal gonadotrophins for ovarian stimulation.
Trial: 31558426
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (n=42)
Trial: 25197669
Drug: 150 IU
RxNorm normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU r-LH for 4 days followed by 400 IU r-FSH after downregulation with daily GnRh agonist
Trial: 22803101
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with mesalazine
Trial: 22803101
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with mesalazine and dalargin
Trial: 19565392
Drug: Traditional dysarthria
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional dysarthria therapy
Trial: 16307694
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg at week 0 and week 2, followed by either placebo or infliximab (5 or 10 mg/kg) every 8 weeks or episodically on loss of response.
Trial: 16307694
Drug: Infliximab treatment
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab treatment (5 or 10 mg/kg)
Trial: 12004211
Drug: Inulin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (24 g daily for 3 weeks)
Trial: 10460604
Drug: Treatment-related mortality
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related mortality during induction and first remission of AML
Trial: 1164639
Drug: Clobetasone butyrate
RxNorm normalized name: clobetasone butyrate
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clobetasone butyrate 0.05% ointment and cream
Trial: 30476460
Drug: 16.2 g
RxNorm normalized name: DODECYLBENZENESULFONIC ACID 16.2 g in 1 L TOPICAL SOLUTION [Opti Blue]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.2 g (270 mg I/mL)
Trial: 30476460
Drug: 16.0 g
RxNorm normalized name: Glycerin 16.0 g in 200 mL TOPICAL GEL [Aloe Soothing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.0 g (320 mg I/mL)
Trial: 30476460
Drug: DECTA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DECTA (both doses)
Trial: 28528472
Drug: Daily assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily assay of serum calcium and phosphorus (Control)
Trial: 19817885
Drug: 27 tablets
RxNorm normalized name: RED 27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27 tablets of 10 mg rizatriptan ODT per month
Trial: 19817885
Drug: 9 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 tablets of 10 mg rizatriptan ODT per month
Trial: 17766654
Drug: Adjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy for women with endocrine-responsive disease
Trial: 17766654
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for postmenopausal women with endocrine nonresponsive early breast cancer
Trial: 15001822
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 178 mg
Trial: 15001822
Drug: Bupropion (BUP)
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion (BUP) 150 mg
Trial: 11443512
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times a day plus psyllium mucilloid 6.0 g
Trial: 11443512
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times a day plus placebo
Trial: 11443512
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus orlistat 120 mg three times a day
Trial: 11443512
Drug: Psyllium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium plus orlistat 120 mg three times a day
Trial: 8231168
Drug: HSV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV with patch
Trial: 8231168
Drug: Control (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (subcutaneous infusion of pentagastrin and carbachol)
Trial: 3306780
Drug: Calf lung
RxNorm normalized name: Calf lung surfactant extract (CLSE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf lung surfactant extract (CLSE) 90 mg by intratracheal instillation
Trial: 29395119
Drug: Ranibizumab (RBZ)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP)
Trial: 29395119
Drug: Panretinal photocoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panretinal photocoagulation (PRP) monotherapy
Trial: 23088936
Drug: Intravenous nifekalant
RxNorm normalized name: Nifekalant
DrugBank: Nifekalant (DB16008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nifekalant (0.3mg/kg)
Trial: 23088936
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous nifekalant (no-AAD group)
Trial: 21406472
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus trastuzumab (L+T)
Trial: 21406472
Drug: Single-agent lapatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent lapatinib (L)
Trial: 16431307
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical treatment (biofeedback training and/or laxative treatment)
Trial: 8646485
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy and HSCT (specific regimens not detailed)
Trial: 24075485
Drug: Sivelestat (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivelestat (0.2 mg/kg per hour)
Trial: 17223855
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg twice daily for 2 days
Trial: 17223855
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice 200 ml three times daily for 2 days
Trial: 15452189
Drug: Cognitive-existential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-existential group therapy (CEGT) with 20 sessions of weekly group therapy plus three relaxation classes (n = 154)
Trial: 12106752
Drug: Vitamin B(6)
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B(6) 50 mg plus placebo pill/day
Trial: 12106752
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg plus placebo pill/day
Trial: 12106752
Drug: Vitamin B(6)
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B(6) 50 mg plus vitamin C 500 mg/day
Trial: 12106752
Drug: 2 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo pills/day (control)
Trial: 8529731
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic cisplatin, methotrexate and vinblastine chemotherapy
Trial: 2311149
Drug: Edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1 mg.kg‐1 (single dose)
Trial: 2311149
Drug: Edrophonium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.2 mg.kg‐1 followed by 0.8 mg.kg‐1 (divided doses)
Trial: 367874
Drug: Glucagon (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (administered intramuscularly and intravenously)
Trial: 6832198
Drug: Alinidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine (0.5 mg/kg i.v.)
Trial: 26324738
Drug: Cixutumumab 10
RxNorm normalized name: Cixutumumab
DrugBank: Cixutumumab (DB12250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab 10 mg/kg and the same antiestrogen (arm A)
Trial: 26324738
Drug: Cixutumumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab (10 mg/kg) with or without antiestrogen
Trial: 26324738
Drug: Lower IR-A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower IR-A, IR-B, and total IR mRNA expression in tumor tissue (regardless of treatment)
Trial: 11244227
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream (Daivonex/Dovonex) used daily combined with UVB treatments twice weekly
Trial: 11244227
Drug: Emollient used
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient used daily combined with UVB treatments three times weekly
Trial: 22014603
Drug: Variable dosing
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable dosing of intravitreal bevacizumab (1.25 mg/0.05 mL)
Trial: 22014603
Drug: Fixed-interval dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-interval dosing of intravitreal bevacizumab (every 4 to 6 weeks)
Trial: 20577706
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine patches (LP) as an add-on to established pain medication